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Abstract
Allitridi (diallyl trisulfide) is an active compound (volatile oil) from garlic. The previous studies reported that allitridi had anti-
arrhythmic effect. The potential ionic mechanisms are, however, not understood. The present study was designed to
determine the effects of allitridi on cardiac potassium channels expressed in HEK 293 cells using a whole-cell patch voltage-
clamp technique and mutagenesis. It was found that allitridi inhibited hKv4.3 channels (IC50 = 11.4 mM) by binding to the
open channel, shifting availability potential to hyperpolarization, and accelerating closed-state inactivation of the channel.
The hKv4.3 mutants T366A, T367A, V392A, and I395A showed a reduced response to allitridi with IC50s of 35.5 mM, 44.7 mM,
23.7 mM, and 42.4 mM. In addition, allitridi decreased hKv1.5, hERG, hKCNQ1/hKCNE1 channels stably expressed in HEK 293
cells with IC50s of 40.2 mM, 19.6 mM and 17.7 mM. However, it slightly inhibited hKir2.1 current (100 mM, inhibited by 9.8% at
2120 mV). Our results demonstrate for the first time that allitridi preferably blocks hKv4.3 current by binding to the open
channel at T366 and T367 of P-loop helix, and at V392 and I395 of S6 domain. It has a weak inhibition of hKv1.5, hERG, and
hKCNQ1/hKCNE1 currents. These effects may account for its anti-arrhythmic effect observed in experimental animal models.
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Introduction
Garlic (Allium sativum L.) and its constituents have been reported
to have multiple beneficial effects including anti-microbial effects
[1], anti-cancer [2,3,4,5], lowering blood pressure [6,7], cardiac
protection against ischemia/reperfusion insult [8,9], reducing
serum cholesterol [2], inhibiting angiogenesis [5,7], enhancing
thrombolysis [10], and also anti-arrhythmic effect [11]. However,
the mechanisms underlying these beneficial effects are not fully
understood, and the ionic mechanism of garlic constituents for
anti-arrhythmic effect is unclear.
A recent report demonstrated that allitridi selectively inhibited
the transient outward potassium current Ito and had no significant
effect on the ultra-rapidly delayed rectifier potassium current IKur
and L-type calcium current (ICa.L) in human atrial myocytes [12].
However, the anti-arrhythmic effect and the prolongation of
cardiac action potential duration and effective refractory period
reported previously with allitridi and/or garlic constituents
[11,13,14] can not fully interpreted by the inhibition of cardiac
Ito, because the 4-aminopyridine-sensitive Ito was not expressed in
cardiac myocytes in some species (e.g. guinea pigs and pigs)
[15,16]. On the other hand, it is unknown the molecular
determinants of allitridi for inhibiting cardiac Ito. The present
study was therefore designed to determine the molecular
determinants of allitridi for blocking Kv4.3 channels (coding
human cardiac Ito) [17], and to investigate whether allitridi would
inhibit other cardiac potassium channels stably expressed in HEK
293 cells, including hERG (coding human cardiac IKr, rapidly-
delayed rectifier potassium current) [18], hKCNQ1/hKCNE1
(coding human cardiac IKs, slowly-delayed rectifier potassium
current) [19], hKv1.5 (coding human cardiac IKur) [20], and
hKir2.1 channels (coding human cardiac IK1, inward rectifier
potassium current) [21] stably expressed in HEK 293 cells using
mutagenesis and whole-cell patch voltage-clamp techniques. Our
results demonstrated that allitridi preferably blocked hKv4.3
channels by interaction with the sites of P-loop helix and S6
domain of the channel, and it also inhibited hKv1.5 channels,
hERG channels, and hKCNQ1/hKCNE1 channels expressed in
HEK 293 cells with a relatively weak effect.
Materials and Methods
Cell Culture, Mutagenesis and Gene Transfection
The established HEK 293 cell lines stably expressing hKv4.3
(KCND3) [22], hKv1.5 (KCN5A) [23,24], hERG (Kv11.1 or
KNCH2) [25], hKCNQ1/hKCNE1 [26], and hKir2.1 [27],
respectively, were cultured in Dulbecco’s modified eagle’s medium
(DMEM, Invitrogen, Hong Kong) supplemented with 10% fetal
bovine serum and corresponding selective antibiotics. The hKv4.3
channel mutants, T366A, T367A, V392A, I395A and V399A
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generated using the QuickChange Site-directed Mutagenesis kit
(Stratagene, La Jolla, CA, USA), were transiently expressed in
HEK 293 cells with a 36-mm culture dish using 10 ml of
Lipofectamine 2000 with 4 mg of hKv4.3 mutant cDNA in
pcDNA3 vector. The point mutants were confirmed with DNA
sequencing. Cells used for electrophysiology were seeded on a glass
cover slip.
Solutions and Chemicals
Tyrode solution contained (mM) NaCl 140, KCl 5.4, MgCl2
1.0, CaCl2 1.8, NaH2PO4 0.33, 4-(2-hydroxyethyl)-1-piperazi-
neethanesulfonic acid (HEPES) 10.0 and glucose 10 (pH adjusted
to 7.3 with NaOH). The pipette solution contained (mM) KCl 20,
K-aspartate 110, MgCl2 1.0, HEPES 10, ethyleneglycoltetraacetic
acid (EGTA) 5, GTP 0.1, Na- phosphocreatine 5, and Mg-ATP 5
(pH adjusted to 7.2 with KOH). Allitridi was obtained from
Qingjiang Pharmaceutical (Nanjing, Jiangshu, China). All other
reagents were obtained from Sigma-Aldrich (St. Louis, MO).
Electrophysiology
Cells on a coverslip were transferred to an open cell chamber
(0.5 ml) mounted on the stage of an inverted microscope and
superfused with Tyrode solution at ,2 ml/min. The whole cell
patch-clamp technique was used as described previously [22–27].
The whole-cell membrane currents were measured using an EPC-
10 amplifier and Pulse software (Heka Elektronik, Lambrecht,
Germany). Borosilicate glass electrodes (1.2-mm OD) were pulled
with a Brown/Flaming puller (model P-97, Sutter Instrument,
Nato, CA) and had resistances of 2–3 MV when filled with the
pipette solution. A 3-M KCl agar bridge was used as the reference
electrode. The tip potential was zeroed before the patch pipette
contacted the cell. After the giga-Ohm seal was obtained, the cell
membrane was ruptured by applying gentle pressure to establish
a whole-cell configuration. Series resistance (Rs) was 4–6 MV and
was compensated by 50–70% to minimize voltage errors. The
liquid junction potential (14.7 mV) calculated with the software
Clampex was not corrected in the experiment and data analysis.
Cell membrane capacitive transient was electrically compensated
with the Pulse software. Current and voltage signals were low-pass
filtered at 5 kHz and stored in the hard disk of an IBM compatible
computer. All experiments were conducted at room temperature
(22–23uC).
Statistical Analysis
The data are expressed as mean6SEM. Paired and/or
unpaired Student’s t-test were used as appropriate to evaluate
the statistical significance of differences between two group means,
and ANOVA was used for multiple groups. Values of P,0.05
were considered to be statistically significant.
Results
Inhibition of hKv4.3 Current by Allitridi
The previous study reported that the IC50 of allitridi for
inhibiting human atrial Ito was about 45 mM [12]. Here we
initially used a concentration of 30 mM allitridi to determine the
potential inhibition of hKv4.3 current stably expressed in HEK
293 cells. Considering that allitridi is a volatile sulfate compound
[28], the experimental working bath solution with 30 mM allitridi
was immediately prepared before the drug application. The
hKv4.3 current recorded with 300-ms voltage step to +60 mV
from a holding potential of 280 mV was rapidly inhibited by
30 mM allitridi. The inhibitory effect reached a steady-state level
within 130 s application, and was gradually reversed by washout
(Fig. 1A). Significant inhibition of voltage-dependent hKv4.3
current could also be observed with 10 mM allitridi (Fig. 1B).
Figure 1C illustrates the current-voltage relationships of mean
values of hKv4.3 current in the absence and presence of 10 and
30 mM allitridi. Allitridi significantly inhibited the current at test
potentials of 210 to +60 mV (n= 16, P,0.05 or P,0.01 vs.
control). It is interesting to note that the current (at +60 mV) was
inhibited by 46% and 78% with 10 and 30 mM allitridi and the
inhibitory efficacy of hKv4.3 current by allitridi is much stronger
than that in human atrial Ito reported previously [12]. We also
observed a weak blocking effect of hKv4.3 current with a pre-
prepared allitridi working solution (40–50% inhibition with 30 mM
allitridi, data not shown). The different efficacy suggests that the
immediate preparation of experimental working bath solution is
crucial for obtaining the accurate pharmacological profile of this
volatile compound.
In addition to the reduction of current amplitude, allitridi
induced a facilitation of hKv4.3 current inactivation (Fig. 1A and
1B), this suggests that allitridi may block the open channels. To
demonstrate the open channel blocking properties, we normalized
Figure 1. Effect of allitridi on hKv4.3 current. A. Time course of
hKv4.3 step current recorded in a representative HEK 293 cell stably
expressing KCND3 gene in the absence and presence of 30 mM allitridi
with a 300-ms test pulse from –80 to +60 mV (inset). Original current
traces at corresponding time points are shown in right side of the
panel. B. Voltage-dependent hKv4.3 current traces recorded in another
cell using the protocol as shown in the inset in the absence and
presence of 10 mM allitridi. C. Current-voltage (I-V) relationships of
hKv4.3 current in the absence and presence of 10 and 30 mM allitridi
(n = 18, P,0.05 or P,0.01 vs. control at 210 to +60 mV).
doi:10.1371/journal.pone.0051550.g001
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the current traces, measured the time to peak of hKv4.3 current,
and fitted the inactivation process with a mono-exponential
equation in the absence and presence of 10 and 30 mM allitridi.
The normalized current at +60 mV showed a quick inactivation
and a reduced time to peak of current activation in a representative
cell (Fig. 2A). Figure 2B and 2C illustrate the mean values of the
time to peak of activation and the time constant (tau) of
inactivation. The time to peak of hKv4.3 activation and the time
constant of hKv4.3 current inactivation were significantly reduced
at all test potentials (210 to +60 mV) by 10 and 30 mM allitridi
(P,0.01 vs. control). The acceleration of the activation (time to
peak) and the inactivation time constant indicates that allitridi
inhibits hKv4.3 current by blocking the open channel.
Figure 3 displays the effect of allitridi on kinetics of hKv4.3
current. Figure 3A and 3B shows the representative current and
voltage protocol used for determining the availability of hKv4.3
current and the activation with tail current. Figure 3C illustrates
the mean values of the variables of availability (I/Imax) of hKv4.3
current using the protocol as shown in Fig. 3A and the variables of
activation conductance (G/Gmax) measured from the current tail
as shown in Fig. 3B in absence and presence of 10 mM. The
variables of I/Imax and G/Gmax were fitted to a Boltzmann
function in individual cells as described previously [29]. The V1/2
of hKv4.3 channnl availability was negatively shifted by 11.9 mV
(from 236.761.1 mV in control to 248.660.9 mV in 10 mM
allitridi, n = 12, P,0.01 vs. control), while the V1/2 of activation
conductance of the current was not altered (3.161.2 mV in
control, 20.261.5 mV in allitridi, n = 10, P=NS vs. control).
Figure 2. Open channel blockade of hKv4.3 by allitridi. A.
Normalized current (+60 mV) in a representative cell before (control)
and after 10 and 30 mM allitridi. The arrow indicates the changes of the
time to peak of the current activation. B. Mean values of the time to
peak of the current activation at 210 to +60 mV before and after
application of 10 and 30 mM allitridi (n = 11 experiments, P,0.01 vs.
control). C. Mean values of time constant of hKv4.3 current inactivation
at 210 to +60 mV before and after application of 10 and 30 mM allitridi
(n = 11 experiments, P,0.01 vs. control).
doi:10.1371/journal.pone.0051550.g002
Figure 3. Effect of allitridi on kinetics of hKv4.3 current. A.
Protocol and current traces used to assess availability (I/Imax, steady-
state inactivation) of hKv4.3 current. B. Protocol and tail current traces
used to assess activation conductance (G/Gmax, steady-state activation)
of hKv4.3 current. C.Mean values of hKv4.3 current (I/Imax) variables and
conductance (G/Gmax) variables before and after 10 mM allitridi were
fitted to the Boltzmann function: g = 1/(1+exp((V1/2-Vt)/K)), where V1/2 is
the voltage of 50% channel availability or maximal activation of the
channel, Vt is the test potential, and K is slope factor. C. Mean values of
recovery time course of hKv4.3 current from inactivation, determined
with protocol as shown in the inset before and after 10 mM allitridi,
were fitted to a mono-exponential function.
doi:10.1371/journal.pone.0051550.g003
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Figure 3D shows the mean values of recovery time course of
hKv4.3 current from inactivation determined by a paired pulse
using a 300-ms step to +50 mV from a holding potential of
280 mV with variable P1–P2 interval as shown in the inset. The
recovery time course was fitted to a mono-exponential function in
individual cells before and after 10 mM allitridi application. The
recovery time constant (t) was 132.164.1 ms in control, and
126.765.1 ms in 10 mM allitridi (n = 10, P =NS vs. control). In
another group of experiments, we found that inhibition of hKv4.3
current by allitridi (10 mM) was use- or rate-independent from
0.2 Hz to 3.3 Hz (n= 6, data not shown). The results suggest that
allitridi has no effect on the recovery of hKv4.3 channels from
inactivation, and is use- or rate-independent inhibition of hKv4.3
current.
Effect of allitridi on closed-state inactivation of hKv4.3
current
The previous study reported that the steady-state inactivation of
Kv4.3 channels occurs predominantly from the closed state [30],
we therefore determined whether allitridi would affect the
development kinetics of closed-state inactivation of hKv4.3
channels. Figure 4A illustrates the closed state inactivation current
traces of hKv4.3 channels in control and after application of
10 mM allitridi. The current was recorded with a double pulses
(300-ms) protocol. A progressively increasing duration of a closed
state potential of250 mV (below activation threshold) was applied
for second pulse. Allitridi (10 mM) clearly accelerated the closed-
state inactivation of hKv4.3 channels. The normalized second
pulse current was plotted against the time duration of closed-state
potential. The closed-state inactivation time course was well fitted
to a mono-exponential function before and after application of
10 mM allitridi (Fig. 4B). The mean values of the inactivation time
constant was 1305625 ms in control, and 713615 ms in 10 mM
allitridi (n = 6, P,0.01 vs. control). The result suggests that allitridi
significantly accelerates the kinetics of closed-state inactivation of
hKv4.3channels.
Molecular determinants of hKv4.3 channel blockade by
allitridi
The molecular determinant of the block of hKv4.3 channels by
allitridi was investigated using hKv4.3 mutants (see Materials and
Method). These mutants are located in the pore- forming area.
T366A and T367A are located in the P-loop helix, while V392A,
I395A, and V399A are located in the S6 transmembrane domain.
Figure 5A shows the representative current traces of wild type
(WT), T366A, T367A, V392A, I395A, and V399A hKv4.3
channels activated with a 300-ms voltage step to +50 mV from
a holding potential of 280 mV in the absence and presence of
30 mM allitridi. This concentration of allitridi remarkably
inhibited the WT and V399A currents. A less inhibition was
observed for the T366A, T367A, V392A, and I395A currents.
The mean values of percentage inhibition of hKv4.3 currents are
illustrated in Fig. 5B. Allitridi at 30 mM inhibited the WT hKv4.3
current by 79.464.4% (n= 18), T366A by 45.269.1% (n= 9,
P,0.01 vs. WT), T367A by 31.566.8% (n= 8, P,0.01 vs. WT),
V392A by 60.668.1% (n= 9, P,0.05 vs. WT), I395A by
36.966.4% (n= 9, P,0.01 vs. WT), and V399A by 74.364.3%
(n= 7, P=NS vs. WT), respectively.
The concentration-dependent response to allitridi was evaluated
in WT and hKv4.3 mutant currents (at +50 mV), and the
concentration-response curves were fitted to a Hill equation as in
Fig. 5C. The IC50s of allitridi in inhibiting the hKv4.3 channels
were 11.4 mM for WT, 35.5 mM for T366A, 44.7 mM for T367A,
23.7 mM for V392A, 42.4 mM for I395A, and 11.2 mM for
V399A, respectively. The Hill co-efficient was in between 1.2 and
1.9 in WT and mutant Kv4.3 channels. These results suggest that
T366, T367, V392, and I395, but not V399, are likely the major
molecular determinants of channel blocking by allitridi.
To determine the relationship between the potential changes in
kinetics of mutant hKv4.3 channels and the drug blocking
sensitivity, we analyzed the availability (I/Imax) and activation
conductance (G/Gmax) of mutant hKv4.3 channels as in Fig. 3.
Figure 6 shows the mean values of the variables of I/Imax and (G/
Gmax) of mutant hKv4.3 channels. The variables were fitted to
a Boltzmann function [29] in individual cells, and the data were
summarized in Table 1. The V1/2 of I/Imax was significantly
shifted to depolarization potentials in the mutants T366A, T367A,
V392A, and I395A (P,0.01 vs. WT), but not V399A. Allitridi
30 mM only significantly shifted the V1/2 of I/Imax in WT hKv4.3,
but not in the mutant channels (Table 1). These results suggest that
the residue position is important in determining the availability of
the channel and the sensitivity of hKv4.3 to block by allitridi. The
V1/2 of G/Gmax was slightly shifted to depolarization potentials in
the mutant hKv4.3 channels, which seems not related to the
sensitivity of allitridi for blocking the channel.
Figure 4. Effect of allitridi on closed-state inactivation of
hKv4.3 current. A. The hKv4.3 current traces recorded by the voltage
protocol (inset) used for determining closed-state inactivation kinetics
of the channel in the absence (control) and presence of 10 mM allitridi.
B. Mean values (n = 6) of time course of the closed-state inactivation of
hKv4.3 current was fitted to a monoexpontial equation before (control)
and after application of 10 mM allitridi.
doi:10.1371/journal.pone.0051550.g004
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Effect of Allitridi on hKv1.5 Current
The effect of allitridi on hKv1.5 channels expressed in HEK
293 cells was determined also with the immediately prepared
working solution. Figure 7A shows the hKv1.5 current traces
elicited by 300-ms voltage steps to between 240 and +60 mV
from a holding potential of 280 mV in a representative cell the
absence and presence of allitridi. Allitridi at 30 mM (5 min
exposure) induced a significant increase of the current inactivation,
a typical of open channel blockade. The inhibition was partially
reversed by washout. Figure 7B illustrates the time course of
hKv1.5 current recorded in a typical experiment with a 300-ms
voltage step to +50 mV from a holding potential of 280 mV with
accumulated application of 10, 30, and 100 mM allitridi. Allitridi
at 10 mM induced a slight inhibition, while it at 30 and 100 mM
remarkably suppressed the current. The inhibitory effect was
partially reversed by washout.
Figure 7C displays the I-V relationships of mean values of
hKv1.5 current in the absence and presence of allitridi. Significant
inhibition of hKv1.5 current was observed with 30 and 100 mM
allitridi at test potentials of 210 to +60 mV (n= 6, P,0.05 or
P,0.01 vs. control). The concentration-response curve (Fig. 7D) of
allitridi for inhibiting hKv1.5 current (+50 mV) was fitted to a Hill
equation. The IC50 of allitridi for inhibiting hKv1.5 current was
40.3 mM with a Hill co-efficient of 2.1.
Effect of Allitridi on hERG Channels
The effect of allitridi on hERG channels was determined in
HEK 293 cells stably expressing KCNH2 gene [23,25]. Figure 8A
shows the voltage-dependent hERG current recorded in a typical
experiment with 3-s voltage steps to between 240 and +60 mV,
then to 250 mV from a holding potential of 280 mV in the
absence and presence of allitridi. Allitridi at 30 mM (5 min
exposure) remarkably inhibited hERG step and tail currents, and
the inhibition was partially reversed by washout. Figure 8B
illustrates the I-V relationships of hERG step current (IhERG.step)
and tail current (IhERG.tail) in the absence (control) and presence of
3, 10, and 30 mM allitridi. The step current and tail current of
hERG channels were significantly inhibited by 10 and 30 mM
allitridi at test potentials of 220 to +60 mV (n= 7, P,0.05 or
P,0.01 vs. control). The concentration-response curve of allitridi
for inhibiting IhERG.tail (Fig. 8C) was fitted to a Hill equation. The
IC50 of allitridi for inhibiting IhERG.tail was 19.6 mM with a Hill co-
efficient of 1.5.
Figure 5. Molecular determinants of hKv4.3 channel block by allitridi. A. Current traces recorded in HEK 293 cells expressing WT, T366A,
T367A, V392A, I395A, and V399A hKv4.3 channels, respectively, with a 300-ms voltage step to +50 mV from a holding potential of 280 mV before
(control) and after 30 mM allitridi treatment for 5 min. The arrows indicate the current inhibition levels. B. Mean percent inhibition of WT and mutant
hKv4.3 currents by 30 mM allitridi (n = 18 for control, n = 7–9 for mutants; *P,0.05, **P,0.01 vs. WT). C. Concentration-response relationship curves
were fitted to a Hill equation to obtain the IC50s of allitridi for inhibiting WT and mutant hKv4.3 channels as shown in the inset (n = 7–18 for each
concentration).
doi:10.1371/journal.pone.0051550.g005
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Effect of Allitridi on Cardiac hKCNQ1/hKCNE1 Channels
The effect of allitridi on human cardiac IKs was determined in
HEK 293 cells stably hKCNQ1/hKCNE1 [26,31]. Figure 9A
displays the voltage-dependent IKs current recorded in a represen-
tative cell with 3-s voltage steps to between 260 and +60 mV (20-
mV increment), then to 250 mV from a holding potential of
280 mV in the absence and presence of allitridi. Allitridi at
30 mM (5 min exposure) remarkably inhibited the step and tail
currents of IKs, and the inhibition was partially reversed by
washout. Figure 9B shows the I-V relationships of IKs step current
in the absence (control) and presence of 3, 10, and 30 mM allitridi.
Significant inhibition of the current was observed with 10 and
30 mM allitridi at test potentials of 0 to +60 mV (n= 6, P,0.01 vs.
control). The concentration-response curve of allitridi for inhibit-
ing IKs is illustrated in Fig. 9C, which was fitted to a Hill equation.
The IC50 of allitridi for inhibiting human cardiac IKs was 17.7 mM
with a Hill co-efficient of 1.3.
Effect of Allitridi on hKir2.1 Current
The effect of allitridi on hKir2.1 channels (coding the cardiac
inward rectifier current IK1) was examined in HEK 293 cells stably
expressing KCNJ2 gene [27]. We found that allitridi had no
inhibition on Kir2.1 current at 30 mM that significantly inhibited
Kv4.3 Kv1.5, hERG, and IKs. It induced a slight reduction of
Kir2.1 current at 100 mM (Fig. 10A). The significant inhibition of
Kir2.1 current was observed at test potential of 2120 to
2100 mV (n= 6, P,0.05 vs. control) (Fig. 10B). Kir2.1 current
at 2120 mV was inhibited by 9.8% with 100 mM allitridi.
Discussion
The present study demonstrates that allitridi preferably blocks
hKv4.3 channels (coding human cardiac Ito) expressed in HEK
293 cells (IC50 = 11.4 mM) by binding to T366 and T367 of the P-
loop helix, and V392 and I395 of the S6 domain of the channel. In
addition, allitridi may also suppress other human cardiac
potassium channels expressed in HEK 293 cells with a relatively
weak effect, including hKv1.5 channels (coding human atrial IKur,
IC50 = 40.3 mM), hERG channels (coding human cardiac IKr,
IC50 = 19.6 mM), hKCNQ1/hKCNE1 channels (coding human
cardiac IKs, IC50 = 17.7 mM). It slightly decreases hKir2.1
channels (coding human cardiac IK1, by 9.8% with 100 mM
allitridi). Therefore, the efficacy of allitridi for inhibiting human
cardiac potassium currents is Ito.IKs.IKr.IKur..IK1. In
addition, we have shown that the inhibitory efficacy of allitridi
on hKv4.3 and hKv1.5 currents is stronger than that observed
previously in human atrial Ito and IKur [12], which suggests that
the fresh preparation of the experimental working solution is
important for the accurate pharmacological effect of this volatile
compound. It may be non-reliable for the relative high concen-
tration for inhibiting human atrial Ito observed in the previous
study [12] and for blocking Kv4.3 current using a pre-prepared
allitridi working solution. In addition, the previous report
demonstrated that allitridi is a major biologically active volatile
organosulfur compound in garlic (with a concentration of 1.1 mg/
g) [32]. Whether the concentration of allitridi in garlic will have an
impact on cardiac K+ channels function remains to be studied.
In addition to the anti-microbial effects [1,33,34], garlic and its
constituents including allitridi were reported to have anti-cancer
effects by inducing G2/M phase cell cycle arrest and apoptosis via
inhibiting PI3K/Akt activation and modulating Bcl-2 family
proteins [2,35,36]. The in vitro and in vivo studies showed that
garlic and its bioactive compounds have multiple cardiovascular
beneficial effects via inhibiting enzymes involved in lipid synthesis,
reducing blood platelet aggregation and cholesterol, lowering
blood pressure, and increasing antioxidant status [37]. Earlier
studies demonstrated that garlic and its extract had anti-
arrhythmic effects in ventricular tachycardia/fibrillation induced
Figure 6. Alteration of availability and activation conductance
of mutant hKv4.3 channels. A. Mean values of the variables of
availability (I/Imax) of WT and mutant hKv4.3 channels. B.Mean values of
the variables of activation conductance (G/Gmax) of WT and mutant
hKv4.3 channels.
doi:10.1371/journal.pone.0051550.g006
Table 1. Effects of allitridi (30 mM) on midpoint potential (V1/
2) of availability (I/Imax) and activation (G/Gmax) of WT and
mutant hKv4.3 channels.
Type Availability (V1/2, mV) Activation (V1/2, mV)
Control Allitridi n Control Allitridi n
WT 236.761.1 248.660.9##12 3.161.2 20.261.5 10
T366A 25.961.3** 29.261.1 8 6.361.1 4.361.2 7
T367A 28.861.4** 211.461.1 7 7.461.3 4.761.1 6
V392A 22.161.2** 25.361.3 6 9.361.6 8.161.3 6
I395A 23.161.4** 25.161.1 7 11.461.3* 9.161.5 7
V399A 233.161.5 230.761.4 8 12.861.5* 11.261.4 7
*P,0.05;
**P,0.01 vs. WT;
##P,0.01 vs. control.
doi:10.1371/journal.pone.0051550.t001
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by ischemia/reperfusion in rats [38,39], and ventricular arrhyth-
mias induced by ouabain or isoproterenol in pigs and atrial
arrhythmia in rats [11]. Rat atrial refractory period was prolonged
by garlic dialysate in a concentration-dependent manner [11].
Recent studies showed that garlic extract improved defibrillation
efficacy, and significantly decreased the inducibility of ventricular
arrhythmia in a dose-dependent manner in a pig model [40,41]. A
more recent study has reported that allitridi has cardioprotective
action against cardiac ischemia/reperfusion injury in a mouse
model via releasing H2S which exerts a preconditioning effect
[42]. However, the prolongation of cardiac effective refractory
period by allitridi in isolated cardiac tissues/hearts [11,13,14] can
not be fully interpreted by the in vivo H2S release mechanism. The
blockade of multiple cardiac potassium channels by effective
concentrations of allitridi observed in the present study may
account for the alteration of cardiac electrophysiology and the
anti-arrhythmias.
The transient outward potassium current Ito plays an important
role in repolarization of atrial and ventricular repolarization in
rodent hearts [43]. Blockade of Ito would prolong cardiac action
potential duration and effective refractory period. Therefore,
inhibition of Ito by allitridi may account for the increase of cardiac
effective refractory period and anti-arrhythmia in rats [11,13].
However, no Ito channel expression was observed in pig [15] and
guinea pig [16] hearts, the anti-arrhythmic effect is likely related to
the inhibition of IKr and IKs in the later species [11,13,14].
Previous studies demonstrated that IKs is positively regulated by
Akt/PI3K kinases [44], allitridi releases H2S [8] and therefore
induces an inhibition of Akt/PI3K [45]. Thus, the inhibition of
Figure 7. Effect of allitridi on hKv1.5 current. A. Voltage-
dependent hKv1.5 current recorded in a representative cell with the
voltage protocol as shown in the inset, in the absence and presence of
30 mM allitridi. B. Time-course of hKv1.5 current recorded in a typical
experiment with the voltage protocol (inset) in the absence and
presence of 10, 30, and 100 mM allitridi. Original current traces at
corresponding time points are shown in right side of the panel. C.
Current-voltage (I-V) relationships of hKv1.5 current in the absence and
presence of 10, 30 and 100 mM allitridi (n = 8, P,0.05 or P,0.01 with 30
and 100 mM allitridi vs. control at 210 to +60 mV). D. Concentration-
response relationship curve of allitridi for inhibiting hKv1.5 current was
fitted to a Hill equation (n = 6–8 for each concentration).
doi:10.1371/journal.pone.0051550.g007
Figure 8. Inhibition of hERG channels by allitridi. A. Voltage-
dependent hERG current recorded in a representative cell with the
voltage protocol as shown in the inset, in the absence and presence of
30 mM allitridi. B. Current-voltage (I-V) relationships of hERG step
current (IhERG.step) and tail current (IhERG.tail) in the absence and presence
of 3, 10, and 30 mM allitridi (n = 7, P,0.05 or P,0.01 with 30 and
100 mM allitridi vs. control at 0 or +10 to +60 mV). C. Concentration-
response relationship curve of allitridi inhibiting hERG tail current was
fitted to a Hill equation (n = 6–8 experiments for each concentration.
doi:10.1371/journal.pone.0051550.g008
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Akt/PI3K may contribute at least in part to the decrease of IKs by
allitridi.
It is well recognized that Ito plays an important role in the
repolarization of action potentials in atrial myocytes [46,47,48]
and also the phase 1 fast repolarization of ventricular action
potentials, especially in ventricular epicardium in humans [29,49]
and in dogs [50]. Therefore, preferable blockade of Ito/Kv4.3 and
a weak inhibition of IKur/Kv1.5, IKr/hERG, and IKs by allitridi
would prolong human atrial action potential and may be effective
in anti-atrial fibrillation in humans.
It has been documented that the shift in cardiac repolarizing
current due to a decrease in sodium or calcium channel currents
or an increase in Ito, IK.ATP, IK.ACh, or other outward currents may
induce J-wave syndromes that involve in Brugada syndrome and
early repolarization syndrome, which may trigger life-threatening
arrhythmia [51,52]. The increase of Ito amplitude by gain-of-
function mutations in KCND3-encoded Kv4.3 channels is the
molecular pathogenesis for the lethal arrhythmia in patients with
Brugada syndrome [53]. The Ito blocker 4-aminopyridine restored
the epicardial action potential dome, reduced both transmural and
epicardial dispersion of repolarization, normalized the ST
segment, and prevented phase 2 reentry and ventricular tachy-
cardia/ventricular fibrillation in experimental Brugada syndrome
[51,54]. Allitridi has a strong inhibition of Kv4.3 current. It, as 4-
aminopyridine [51,54], is likely effective in suppressing Brugada
syndrome-related arrhythmias. However, it remains to be studied
in the future.
We found that the allitridi inhibited Kv4.3 channels by shifting
the availability voltage to more negative potentials and acceler-
ating the closed-state inactivation of the channel. It significantly
reduced the time to peak of current activation and the time
constant of Kv4.3 current inactivation. This suggests that allitridi
may quickly bind the channel when they open. However, allitridi,
as rosiglitazone [55], blocked the open channels of hKv4.3 in a use-
or rate-independent manner. The open channel blocking effect
was also observed in Kv1.5 current.
Alanine-scanning mutagenesis is a method of systematic alanine
substitution and has been particularly used for the identification of
functional epitopes [56]. This technique is usually used for
identifying the drug binding sites of ion channel blockers
[24,57,58]. With this technique, we demonstrated that the
inhibitory efficacy of allitridi on the hKv4.3 mutants T366A and
T367A at the P-loop of the pore helix was significantly reduced.
This implies that allitridi may be trapped into the channel pore
and block the open channel. Moreover, the mutants V392A and
Figure 9. Inhibition of human cardiac IKs by allitridi. A. Voltage-
dependent human cardiac IKs recorded in a representative HEK 293 cells
expressing hKCNQ1/hKCNE1 genes with the voltage protocol as shown
in the inset, in the absence and presence of 30 mM allitridi. B. Current-
voltage (I-V) relationships of IKs step current in the absence and
presence of 3, 10, and 30 mM allitridi (n = 8, P,0.05 or P,0.01 with 30
and 100 mM allitridi vs. control at 0 to +60 mV). C. Concentration-
response relationship curve of allitridi inhibiting IKs was fitted to a Hill
equation (n = 5–8 for each concentration).
doi:10.1371/journal.pone.0051550.g009
Figure 10. Effect of allitridi on hKir2.1 current. A. Voltage-
dependent hKir2.1 current recorded in a representative cell with the
voltage protocol as shown in the inset, in the absence and presence of
100 mM allitridi. C. Current-voltage (I-V) relationships of hKir2.1 current
before (control) and after application of 100 mM allitridi (n = 6, *P,0.05
vs. control).
doi:10.1371/journal.pone.0051550.g010
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I395A, but not V399A, of the S6 domain exhibit a significantly
reduced response to allitridi, indicating that in addition to binding
to the P-helix filter, allitridi may interact with V392 and I395 of
the S6 domain. Therefore, these four residues (T366, T367, V392,
and I395) of the channel are likely critical for allitridi inhibition of
hKv4.3 current.
Collectively, the present study demonstrates that allitridi blocks
hKv4.3 channels by interacting with T366 and T367 of the P-loop
helix, and V392 and I395 in the S6 domain, and also has
a relatively weak inhibition of hKv1.5, hERG, and IKs. These
effects may count for anti-arrhythmias observed in experimental
arrhythmic animal models.
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